

UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF NEW JERSEY

In re: Tri Harbor Holdings Corporation (f/k/a Aceto Corporation), et al.

Case No. (Jointly Administered)
Reporting Period:
Federal Tax I.D. #

19-13448
August 1 - August 31, 2019
11-1720520

CORPORATE MONTHLY OPERATING REPORT

REQUIRED DOCUMENTS	Form No.	Document Attached	Explanation Attached
Schedule of Cash Receipts and Disbursements	MOR-1	X	
Bank Reconciliation (or copies of debtor's bank reconciliations)	MOR-1a	X	See Attestation
Schedule of Retained Professional Fees Paid	MOR-1b	X	
Copies of bank statements (See Notes to the MOR)			X
Cash disbursements journals (See Notes to the MOR)			X
Statement of Operations (Income Statement)	MOR-2	X	
Balance Sheet	MOR-3	X	
Status of Post-petition Taxes	MOR-4	X	See Attestation
Copies of IRS Form 6123 or payment receipt (See Notes to the MOR)			X
Copies of tax returns filed during reporting period (See Notes to the MOR)			X
Summary of Unpaid Post-petition Debts (See Notes to the MOR)	MOR-4a		X
Listing of Aged Accounts Payable (See Notes to the MOR)	MOR-4a		X
Accounts Receivable Reconciliation and Aging (See Notes to the MOR)	MOR-5		X
Debtor Questionnaire	MOR-6	X	

I declare under penalty of perjury (28 U.S.C. Section 1746) that this report and the attached documents are true and correct to the best of my knowledge and belief.

/s/ Steven S. Rogers
Signature of Authorized Individual*

October 4, 2019
Date

Steven S. Rogers
Printed Name of Authorized Individual

Plan Administrator
Title

*Authorized individual must be an officer, director or shareholder if debtor is a corporation; a partner if debtor is a partnership; a manager or member if debtor is a limited liability company.

In re: Tri Harbor Holdings Corporation (f/k/a Aceto Corporation), et al.

MOR Notes
19-13448
Case No. (Jointly Administered)
Reporting Period: August 1 - August 31, 2019
Federal Tax I.D. # 11-1720520

Notes to the Monthly Operating Report

GENERAL:

The report includes activity from the following Debtors and related Case Numbers:

Debtor	Case Number	Debtor	Case Number
Tri Harbor Holdings Corporation (f/k/a Aceto Corporation)	19-13448	Kavris Health, LLC (fka Acetris Health, LLC)	19-13452
Tri Harbor Chemical Holdings LLC (fka Aceto Agricultural Chemical Corporation)	19-13449	Arsynco, Inc.	19-13454
Kavod Pharmaceuticals LLC (fka Rising Pharmaceuticals, Inc.)	19-13447	Tri Harbor Realty LLC (fka Aceto Realty LLC)	19-13450
KAVACK Pharmaceuticals LLC (fka PACK Pharmaceuticals, LLC)	19-13453	Acci Realty Corp.	19-13455
Kavod Health LLC (fka Rising Health, LLC)	19-13451		

Notes to the MOR:

This Monthly Operating Report ("MOR") has been prepared solely for the purpose of complying with the monthly reporting requirements applicable in these chapter 11 cases and is in a format acceptable to the U.S. Trustee. The financial information contained herein is unaudited, limited in scope, and, as discussed below, is not prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").

The unaudited financial statements have been derived from the books and records of Tri Harbor Holdings Corporation (f/k/a Aceto Corporation) and its affiliated debtors (collectively, the "Debtors"). The information furnished in this report includes primarily normal recurring adjustments, but not all of the adjustments that would typically be made for the quarterly and annual financial statements to be in accordance with U.S. GAAP. Furthermore, the monthly financial information contained herein has not been subjected to the same level of accounting review and testing that the Debtors apply in the preparation of their quarterly and annual financial information in accordance with U.S. GAAP. Accordingly, upon the application of such procedures, the Debtors believe that the financial information may be subject to change, and these changes could be material.

The financial statements presented in MOR-2 and MOR-3 do not include elimination entries for intercompany balances related to non-debtor affiliates. Investment in subsidiary balances are recorded at cost which may not be in accordance with U.S. GAAP. The amounts currently classified as liabilities subject to compromise may be subject to future change as the Debtors complete their analysis of prepetition liabilities.

Amounts listed in the statement of operations and balance sheet in the attached MOR-2 and MOR-3 now reflect the completed review of the financial information provided by the purchasers (the "Buyers") of the assets of the Debtors' Pharma Business and Chemical Plus ("ChemPlus") Business as described in the relevant Asset Purchase Agreements and related documents filed previously with this Court. As a result of the review, the Debtors' income statement for August 31st represents a \$1.5 million gain on the sales of the assets. Though the Debtors have completed their review of such financial information, the Debtors reserve their rights to make further adjustments as may be needed. Accordingly, the Debtors reserve the right to amend this MOR.

Pursuant to the Court's order establishing deadlines to file proofs of claim [Docket No. 509], the General Bar Date (as defined therein) for non-governmental units was June 19, 2019, and the Governmental Bar Date (as defined therein) was August 19, 2019. The Governmental Bar Date was extended to October 15, 2019 solely for the Antitrust Division of the U.S. Department of Justice and the U.S. Department of Health and Human Services. The Debtors are in the process of reviewing and reconciling the claims filed to date and expect this process will continue for several months. There are many claims asserting amounts that are not reflected in the Debtors' books and records that were relied upon for the completion of this MOR. To the extent those claims are allowed or otherwise deemed valid during the claims reconciliation process, the Debtors' books and records will be adjusted accordingly.

The results of operations contained herein are not necessarily indicative of results which may be expected from any other period or for the full year and may not necessarily reflect the consolidated results of operations, financial position, and cash flows of the Debtors in the future. The Debtors caution readers not to place undue reliance upon the MOR. Such information may be incomplete and the MOR may be subject to revision.

The financial statements contained herein do not include any accruals or estimates for an estate wind-down budget. Accordingly, they should not be relied upon as an indicator of recoveries. Reference should be made to the Second Modified Joint Plan of Liquidation (the "Plan") [Docket No. 757] and Second Modified Disclosure Statement (the "Disclosure Statement") [Docket No. 758] for information regarding estimated creditor recoveries.

Notes to MOR-1a:

The Debtors maintain 25 total bank accounts (collectively, the "Bank Accounts") at several financial institutions (the "Banks"). The Bank Accounts vary in purpose and function across the Debtors, and each Debtor's Bank Accounts serve its respective business accordingly.

Notes to MOR-2:

The Income Statement reflects revenue and expenses for the reporting month of August 2019 that directly correspond to the listed debtor legal entity. Amounts reported may not reflect gain/loss for tax purposes.

In re: Tri Harbor Holdings Corporation (f/k/a Aceto Corporation), et al.

Case No. (Jointly Administered)	MOR Notes
Reporting Period:	19-13448
	August 1 - August 31, 2019
Federal Tax I.D. #	11-1720520

Notes to the Monthly Operating Report

Notes to MOR-3:

The Balance Sheet reflects assets, liabilities, and stockholders equity that directly correspond to the debtor legal entity.

As a result of the commencement of these chapter 11 cases, the payment of prepetition indebtedness is subject to compromise or other treatment under a chapter 11 plan. The Court authorized the Debtors to pay certain prepetition claims, including, but not limited to, certain trade and tax claims. To the extent such claims have been categorized as "Liabilities Not Subject to Compromise," the Debtors reserve their right to dispute their obligation to make such payments. The Debtors have been paying, and intend to continue to pay, undisputed post-petition claims arising in the ordinary course of business.

The liability information contained herein, except as otherwise noted, is listed as of the close of business as of the end of the month. Accordingly, the Debtors reserve all rights to amend, supplement, or otherwise modify this MOR as necessary and appropriate, but shall be under no obligation to do so. The Debtors have paid certain prepetition liabilities pursuant to orders entered by the Court that authorize such payments. The Debtors believe that all undisputed post-petition accounts payable have been and are being paid according to agreed-upon terms specific to each vendor and/or service provider and as authorized by the Court. In addition, the liabilities reported in this MOR do not reflect any analysis conducted by the Debtors regarding potential claims under section 503(b)(9) of the Bankruptcy Code. Accordingly, the Debtors reserve any and all of their rights to dispute or challenge the validity of any claims asserted under section 503(b)(9) of the Bankruptcy Code or the characterization of the structure of any transaction, document, or instrument related to any creditor's claim.

Intercompany accounts have not been reclassified to LSTC, nor have any Income Taxes Payable. In addition, income taxes payable and receivable are shown at gross amounts in these financial statements and have not been netted.

The amount reported in LSTC for the Unsecured Convertible Notes includes principal and accrued interest through the Petition Date.

The deferred payment obligation that arose in connection with the purchase of Citron Pharma and Lucid Pharma in 2016 has been adjusted to \$30 million pursuant to the the Asset Purchase Agreement regarding the sale of the assets of the Pharma Business and mutual release executed in connection therewith, which was approved by the Court by order entered on April 10, 2019 [Docket No. 373]. This amount is included in LSTC for Kavod Pharmaceuticals LLC.

The Tri Harbor Chemical Holdings LLC (f/k/a Aceto Agriculture Chemical Corporation) interest in Canegrass LLC, a joint venture ("JV"), was formally dissolved in August as authorized by the Court pursuant to the Stipulation and Consent Order (A) In Furtherance of Order Approving the Sale of the Debtors Chemical Plus Business and (B) Regarding Resolution of Debtors Interests in Non-Debtor Canegrass LLC and Related Agreements [Docket No. 791] (the "Canegrass Stipulation"). In connection with such dissolution and as authorized pursuant to the Canegrass Stipulation, Tri Harbor Chemical Holdings LLC (f/k/a Aceto Agriculture Chemical Corporation) received approximately \$1.9 million in cash.

\$1.9 million of the cash and cash equivalents reported at Arsynco were funded by Tri Harbor Holdings Corporation (f/k/a Aceto Corporation) from proceeds from the sale of the ChemPlus Business to a restricted bank account maintained by Arsynco with JPMorgan Chase Bank, N.A. (the "Remediation Funding Source Bank Account") to backstop certain remediation obligations of Arsynco in connection with Arsynco's property (a former chemicals manufacturing plant) located at 511 13th Street in Carlstadt, New Jersey (the "Arsynco Carlstadt Property"). On September 4, 2019, the Court entered an order (the "Arsynco Sale Order") approving the sale of the Arsynco Carlstadt Property to 511 Thirteenth Street LLC ("Arsynco Purchaser"). The treatment of such the funds held in the Remediation Funding Source Bank Account depends, in part, upon the outcome of the sale of the Arsynco Carlstadt Property. Specifically, as set forth in the Arsynco Sale Order, upon the closing of the sale of the Arsynco Carlstadt Property to the Arsynco Purchaser, the Debtors are authorized and directed to transfer all funds held in the Remediation Funding Source Bank Account to Tri Harbor Holdings Corporation (f/k/a Aceto Corporation) and no claims or interests of any party holding a claim or interest against Arsynco or the Arsynco Purchaser shall attach to any portion of the funds held in the Remediation Funding Source Bank Account.

Notes to MOR-4:

The Debtors received authority pursuant to various "first day" orders to pay certain prepetition liabilities, including prepetition tax liabilities.

The Debtors are current on all undisputed post-petition payables.

Notes to MOR 4a and MOR 5:

The Debtors disclose the ending accounts receivable and accounts payable balances as part of MOR-3. Due to the volume of transactions related to customer and vendor billings and payments, these items will be made available upon request.

In re: Tri Harbor Holdings Corporation (f/k/a Aceto Corporation), et al.

Case No. (Jointly Administered)

Reporting Period:

Federal Tax I.D. #

MOR-1

19-13448

August 1 - August 31, 2019

11-1720520

Schedule of Cash Receipts and Disbursements

Whole Values

Debtor	Case Number	Cash Receipts	Cash Disbursements
Aceto Corporation	19-13448	\$24,545	\$1,792,283
Tri Harbor Chemical Holdings LLC	19-13449	1,988,036	14,093
Kavod Pharmaceuticals LLC	19-13447	-	4,084
KAVACK Pharmaceuticals LLC	19-13453	-	-
Kavod Health LLC	19-13451	-	-
Kavis Health, LLC	19-13452	-	-
Arsynco, Inc.	19-13454	-	-
Tri Harbor Realty LLC	19-13450	-	-
Acci Realty Corp.	19-13455	-	-
Total Cash Receipts and Cash Disbursements		\$2,012,581	\$1,810,461

Notes:

- Excludes transfers between Debtors.
- Cash receipts and disbursement amounts based on checks cleared, wires, and other transfer of funds. During the period, the Debtors also received and forwarded misdirected funds from customers intended for the purchasers of the Pharma and ChemPlus businesses. Those amounts are excluded from the totals represented herein.

In re: Tri Harbor Holdings Corporation (f/k/a Aceto Corporation), et al.
Case No. (Jointly Administered)
Reporting Period:
Federal Tax I.D. #

MOR-1a
19-13448
August 1 - August 31, 2019
11-1720520

Bank Account Information
Whole Values

Legal Entity	Bank	Last 4 Digits of Account Number	Book Balance
Kavod Pharmaceuticals LLC	Wells Fargo	5236	\$8,225,892
Kavod Pharmaceuticals LLC	Wells Fargo	5244	178,526
Kavris Health, LLC	Wells Fargo	7026	1,818,369
PACK Pharmaceuticals, Inc	Wells Fargo	5771	72
Kavod Health LLC	Valley National Bank	9996	16,282
Kavris Health, LLC	Valley National Bank	9988	5,633
Kavris Health, LLC	Valley National Bank	7066	-
Kavod Health LLC	Valley National Bank	3542	395,489
Aceto Corporation	JP Morgan Chase	8648	52,990,157
Aceto Corporation	JP Morgan Chase	5641	287,499
Aceto Corporation	JP Morgan Chase	6899	22,075 [A]
Acci Realty	JP Morgan Chase	4828	2,740
Arsynco, Inc	JP Morgan Chase	3783	2,039,404 [B]
Tri Harbor Realty LLC	JP Morgan Chase	9364	70,786
Aceto Corporation	Citibank	2449	9,258
Aceto Corporation	Wells Fargo	4853	2,234,161
Aceto Corporation	Wells Fargo	3076	258,603
Aceto Corporation	Wells Fargo	3036	26,758
Aceto Corporation	Wells Fargo	3166	177,892
Aceto Corporation	Wells Fargo	3066	2,479
Tri Harbor Chemical Holdings LLC	Chase	5722	5,082,533
Tri Harbor Chemical Holdings LLC	Wells Fargo	4036	265,377
Tri Harbor Chemical Holdings LLC	Wells Fargo	4166	242,523
Aceto Corporation	Bank of America	1418	- [C]
Aceto Corporation	M&T Bank	6485	125,000,000
			\$199,352,509

Notes to MOR 1-a:

All amounts listed above are the bank balances as of the end of the month. Copies of bank statements and cash disbursement journals are not included in this MOR. These items will be made available upon request.

During the period, the Debtors also received and forwarded misdirected funds from customers intended for the purchasers of the Pharma and ChemPlus businesses. Those amounts are excluded from the totals represented herein.

[A] Account was created to hold the Utility Deposits as defined in, and pursuant to, the interim and final orders regarding the Debtors' utility providers entered on February 21, 2019 and March 15, 2019 [Docket Nos. 41 and 139].

[B] \$1.9 million of the cash and cash equivalents reported at Arsynco were funded by Tri Harbor Holdings Corporation (f/k/a Aceto Corporation) from proceeds from the sale of the ChemPlus Business to a restricted bank account maintained by Arsynco with JPMorgan Chase Bank, N.A. (the "Remediation Funding Source Bank Account") to backstop certain remediation obligations of Arsynco in connection with Arsynco's property (a former chemicals manufacturing plant) located at 511 13th Street in Carlstadt, New Jersey (the "Arsynco Carlstadt Property"). On September 4, 2019, the Court entered an order (the "Arsynco Sale Order") approving the sale of the Arsynco Carlstadt Property to 511 Thirteenth Street LLC ("Arsynco Purchaser"). The treatment of such the funds held in the Remediation Funding Source Bank Account depends, in part, upon the outcome of the sale of the Arsynco Carlstadt Property. Specifically, as set forth in the Arsynco Sale Order, upon the closing of the sale of the Arsynco Carlstadt Property to the Arsynco Purchaser, the Debtors are authorized and directed to transfer all funds held in the Remediation Funding Source Bank Account to Tri Harbor Holdings Corporation (f/k/a Aceto Corporation) and no claims or interests of any party holding a claim or interest against Arsynco or the Arsynco Purchaser shall attach to any portion of the funds held in the Remediation Funding Source Bank Account.

[C] Account is the professional fee escrow account held by Lowenstein Sandler, which was created in connection with the closings of the sales of the assets of the Debtors' businesses for the purpose of paying allowed claims of professionals retained by the Debtors' estates pursuant to the interim compensation procedures order [Docket No. 205] and order authorizing the retention of ordinary course professionals [Docket No. 377].

In re: Tri Harbor Holdings Corporation (f/k/a Aceto Corporation), et al.

Case No. (Jointly Administered)

Reporting Period:

MOR-1a
19-13448
August 1 - August 31, 2019

Federal Tax I.D. #

11-1720520

Bank Reconciliation (or copies of debtor's bank reconciliations)

--	--	--	--	--

The above-captioned debtors (the "Debtors") hereby submit this attestation regarding bank account reconciliations in lieu of providing copies of bank statements, journals, and account reconciliations.

I attest that each of the Debtors' bank accounts is reconciled to bank statements. The Debtors' standard practice is to ensure that each bank account is reconciled to bank statements once per month within 31 days after the month end.

/s/ Steven S. Rogers

Signature of Authorized Individual

October 4, 2019

Date

Steven S. Rogers

Printed Name of Authorized Individual

Plan Administrator

Title of Authorized Individual

In re: Tri Harbor Holdings Corporation (f/k/a Aceto Corporation), et al.

Case No. (Jointly Administered)

Reporting Period:

Federal Tax I.D. #

MOR-1b

19-13448

August 1 - August 31, 2019

11-1720520

Schedule of Retained Professional Fees Paid

Whole Values

Payee	Role of Professional	Amount Paid	Cumulative Payments Since Filing
LOWENSTEIN SANDLER LLP	DEBTORS' COUNSEL	-	\$7,720,012
PJT PARTNERS LP	DEBTORS' INVESTMENT BANKER	121,975	7,871,237
AP SERVICES	DEBTORS' FINANCIAL ADVISOR	513,441	5,201,208
PRIME CLERK	DEBTORS' ADMINISTRATIVE ADVISOR	49,546	542,304
MCGUIREWOODS LLP	LENDERS' COUNSEL	-	860,740
FTI CONSULTING INC.	LENDERS' FINANCIAL ADVISOR	-	102,997
LATHAM & WATKINS	LENDERS' COUNSEL	-	14,502
MCCARTER & ENGLISH	LENDERS' COUNSEL	-	25,398
STROOK & STROOK & LAVAN LLP	COMMITTEE COUNSEL	241,919	2,437,595
PORZIO BROMBERG & NEWMAN, P.C.	COMMITTEE COUNSEL	66,767	716,101
GLASSRATNER	COMMITTEE FINANCIAL ADVISOR	9,255	127,374
KPMG	DEBTORS' TAX CONSULTANT	85,964	606,007
HOULIHAN LOKEY	COMMITTEE INVESTMENT BANKER	-	459,809
		\$1,088,867	\$26,685,283

Notes to MOR 1-b:

- The above does not include payments made to professionals retained pursuant to the Court's order authorizing the retention of ordinary course professionals [Docket No. 377], in the aggregate amounts of \$30,121.47 in August 2019 and \$386,765.16 from the Petition Date through August 2019.

In re: Tri Harbor Holdings Corporation (f/k/a Aceto Corporation), et al.

Case No. (Jointly Administered) MOR-2
19-13448
Reporting Period: August 1 - August 31, 2019
Federal Tax I.D. # 11-1720520

UNAUDITED - August Month Statement of Operations (Income Statement)									
Tri Harbor Holdings Corporation 19-13448 (VFP)	Tri Harbor Chemical Holdings LLC 19-13449 (VFP)	Tri Harbor Realty LLC 19-13450 (VFP)	Arsynco, Inc. 19-13454 (VFP)	Acci Realty Corp. 19-13455 (VFP)	Kavod Pharmaceuticals LLC 19-13447 (VFP)	Kavris Health, LLC 19-13452 (VFP)	KAVACK Pharmaceuticals LLC 19-13453 (VFP)	Kavod Health LLC 19-13451 (VFP)	
Total Sales - Net	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Total Cost of Goods Sold	-	-	-	-	-	-	-	-	-
Gross Margin	-	-	-	-	-	-	-	-	-
Total S,G&A Expenses	(258,468)	(6,193)	-	734,213	-	(3,499)	-	-	-
Total Corporate Overhead Allocation	-	-	-	-	-	(586)	-	-	-
OPERATING PROFIT (LOSS)	\$ (258,468)	\$ (6,193)	\$ -	\$ 734,213	\$ -	\$ (4,084)	\$ -	\$ -	\$ -
Professional Fees - Restructuring	(2,682,700)	-	-	-	-	-	-	-	-
Interest income	12	75	-	-	-	-	-	-	-
Exchange gains realised	14,052	(1,749)	-	-	-	-	-	-	-
Gain / (Loss) On Sale Of Assets & Write-Down of Investment in Subs	1,058,504	234,282	-	-	-	253,077	-	-	-
Provision For Bad Debt	-	-	-	-	-	-	-	-	-
Other financial income	-	-	-	-	-	-	-	-	-
Total Non-Operating Income/(Expense)	(1,610,132)	232,608	-	-	-	253,077	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-
PROFIT/(LOSS) BEFORE TAXES	\$ (1,868,600)	\$ 226,415	\$ -	\$ 734,213	\$ -	\$ 248,993	\$ -	\$ -	\$ -
TOTAL TAXES	-	-	-	-	-	-	-	-	-
NET PROFIT / (LOSS)	\$ (1,868,600)	\$ 226,415	\$ -	\$ 734,213	\$ -	\$ 248,993	\$ -	\$ -	\$ -

The notes to this monthly operating report are an integral part of these combined financial statements.

In re: Tri Harbor Holdings Corporation (f/k/a Aceto Corporation), et al.

Case No. (Jointly Administered) MOR-3
19-13448
Reporting Period: Month Ending August 31, 2019
Federal Tax I.D. # 11-1720520

UNAUDITED - August 31 Balance Sheet										
Tri Harbor Holdings Corporation 19-13448 (VFP)	Tri Harbor Chemical Holdings LLC 19-13449 (VFP)	Tri Harbor Realty LLC 19-13450 (VFP)	Arsynco, Inc. 19-13454 (VFP)	Acci Realty Corp. 19-13455 (VFP)	Kavod Pharmaceuticals LLC 19-13447 (VFP)	Kavris Health, LLC 19-13452 (VFP)	KAVACK Pharmaceuticals LLC 19-13453 (VFP)	Kavod Health LLC 19-13451 (VFP)		
Cash & Cash Equivalents	\$ 180,986,808	\$ 5,590,434	\$ 70,786	\$ 2,039,404	\$ 2,740	\$ 8,816,261	\$ 1,824,002	\$ -	\$ -	
Account receivables Net	-	-	-	-	-	-	-	-	-	
Other receivables	22,075	234,282	1,081	1,416,427	-	-	-	-	-	
Due From/(To) Affiliates	(83,652,195)	29,165,101	(1,711,494)	(17,134,067)	(302,315)	71,385,222	2,127,450	-	-	
Total inventories	-	-	-	-	-	-	-	-	-	
Income Tax Receivable	1,494,550	-	-	-	-	1,397,615	-	-	-	
Prepaid expenses	1,775,851	-	-	-	-	-	-	-	-	
Total Current Assets	\$ 100,627,090	\$ 34,989,817	\$ (1,639,628)	\$ (13,678,236)	\$ (299,576)	\$ 81,599,099	\$ 3,951,452	\$ -	\$ -	
Investments	179,000	11,459	-	-	-	-	-	-	-	
Investments in Subsidiaries & Affiliates	6,580,500	-	-	-	-	-	-	-	-	
Total Investments	6,759,500	11,459	-	-	-	-	-	-	-	
Property, plant & equipment - net	-	-	-	-	-	-	-	-	-	
Total Intangible Assets - Net	-	-	-	-	-	(2)	-	-	-	
Deferred Tax Assets - Net of Allowances	(9,044)	-	-	-	-	-	-	-	-	
Other Assets - LT	237,771	-	-	-	-	5,999	-	-	-	
Property held For Sale - LT	-	-	-	6,112,710	-	-	-	-	-	
Total Long Term Assets	\$ 6,988,227	\$ 11,459	\$ -	\$ 6,112,710	\$ -	\$ 5,997	\$ -	\$ -	\$ -	
Total Assets	\$ 107,615,316	\$ 35,001,276	\$ (1,639,628)	\$ (7,565,526)	\$ (299,576)	\$ 81,605,096	\$ 3,951,452	\$ -	\$ -	
Account payables	104,355	-	-	3,671	-	-	-	-	-	
Accrued Compensation	(0)	-	-	-	-	(0)	-	-	-	
Accrued Income Tax	2,603,419	-	-	-	-	(2,213,291)	-	-	-	
Accrued Environmental Remediation	-	-	-	3,147,616	-	-	-	-	-	
Accrued expenses - Other	6,061,980	55,377	-	-	-	-	-	-	-	
Total Current Liabilities	\$ 8,769,754	\$ 55,377	\$ -	\$ 3,151,287	\$ -	\$ (2,213,291)	\$ -	\$ -	\$ -	
Accrued Income Tax LT	5,322,572	-	-	-	-	-	-	-	-	
Other long-term liabilities	53,211	-	-	-	-	-	-	-	-	
Total Long Term Liabilities	\$ 5,375,783	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	
Total Liabilities Not Subject to Compromise	\$ 14,145,536	\$ 55,377	\$ -	\$ 3,151,287	\$ -	\$ (2,213,291)	\$ -	\$ -	\$ -	
Total Liabilities Subject to Compromise	\$ 144,848,869	\$ -	\$ -	\$ 18,460	\$ -	\$ 36,238,045	\$ -	\$ -	\$ -	
Shareholders' Equity	\$ (51,379,089)	\$ 34,945,899	\$ (1,639,628)	\$ (10,735,273)	\$ (299,576)	\$ 47,580,342	\$ 3,951,452	\$ -	\$ -	
Total Liabilities & Shareholders Equity	\$ 107,615,316	\$ 35,001,276	\$ (1,639,628)	\$ (7,565,526)	\$ (299,576)	\$ 81,605,096	\$ 3,951,452	\$ -	\$ -	

The notes to this monthly operating report are an integral part of these combined financial statements.

In re: Tri Harbor Holdings Corporation (f/k/a Aceto Corporation), et al.

Case No. (Jointly Administered)

Reporting Period:

MOR-4
19-13448
August 1 - August 31, 2019

Federal Tax I.D. #

11-1720520

Status of Post-petition Taxes

--	--	--	--	--

The above-captioned debtors (the "Debtors") hereby submit this attestation regarding Status of Post-petition Taxes in lieu of providing copies of post-petition tax payments and tax returns filed during reporting period.

I attest that each of the Debtors' taxing authorities have been paid on time when post-petition amounts become due. Also, tax returns are being filed in an orderly and timely fashion in accordance with tax return reporting deadlines.

/s/ Steven S. Rogers

Signature of Authorized Individual

October 4, 2019

Date

Steven S. Rogers

Printed Name of Authorized Individual

Plan Administrator

Title of Authorized Individual

In re: Tri Harbor Holdings Corporation (f/k/a Aceto Corporation), et al.

Case No. (Jointly Administered)

Reporting Period:

Federal Tax I.D. #

MOR-6

19-13448

August 1 - August 31, 2019

11-1720520

Debtor Questionnaire

	Must be completed each month.	Yes	No
1	Have any assets been sold or transferred outside the normal course of business this reporting period? If yes, provide an explanation below.		X
2	Have any funds been disbursed from any account other than a debtor in possession account this reporting period? If yes, provide an explanation below.		X
3	Have all postpetition tax returns been timely filed? If no, provide an explanation below.	X	
4	Are workers compensation, general liability and other necessary insurance coverages in effect? If no, provide an explanation below.	X	
5	Has any bank account been opened during the reporting period? If yes, provide documentation identifying the opened account(s). If an investment account has been opened provide the required documentation pursuant to the Delaware Local Rule 4001-3. (SEE MOR NOTES.)		X